From INSIGHTEC Promotional Video
Remember Star Trek’s futuristic surgery without scalpels? Insightec, an Israeli medical technology company, just got $150 million closer to making that vision a reality. The company secured funding to advance its focused ultrasound technology, offering a minimally invasive alternative to traditional surgery.
The funding will support Insightec’s continued development and commercialization of focused ultrasound technology, a non-invasive treatment approach with the potential to transform patient care across various medical fields.
Insightec’s focused ultrasound platform utilizes sound waves to target specific tissues within the body, offering a minimally invasive alternative to traditional surgical procedures. This technology holds promise for treating a variety of conditions, potentially improving patient outcomes and reducing recovery times.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
With this significant investment, Insightec is poised to accelerate its growth and deliver the benefits of focused ultrasound to a wider range of patients.
The Exablate 4000 (Exablate Neuro) platform uses MR-guided focused ultrasound to precisely ablate a small target deep within the brain without incisions. The approval will enable treatment of patients in India living with Essential Tremor, Tremor-dominant Parkinson’s Disease and Neuropathic Pain.
Insightec uses the therapeutic power of acoustic energy for medical care. How? The company’s tech uses the power of sound waves to penetrate the human body so that doctors will no longer need to cut someone open in order to operate.
“We are grateful for the strong support of our mission from these new and existing investors,” said Maurice R Ferré, M.D., CEO and chairman of the board of Insightec. “This financing provides Insightec with runway to expand incisionless neurosurgery to the many patients suffering from movement disorders and continue to make calculated and strategic investments in new indications.”
With over 160 systems installed worldwide, Insightec’s proprietary technology has been used in nearly 20,000 commercial applications and is currently FDA approved as an incisionless, immediate treatment for patients suffering from essential tremor and Parkinson’s disease.
